Skip to main content
Fig. 4 | Stem Cell Research & Therapy

Fig. 4

From: Combination therapy of menstrual derived mesenchymal stem cells and antibiotics ameliorates survival in sepsis

Fig. 4

MenSCs in combination with antibiotics prevent the decrease of CD45+ CD3+ and CD45+ CD19+ lymphocyte levels after CLP-induced sepsis. Blood samples were obtained 24 and 40 hours after administration of various treatments post-CLP, and specific lymphocyte subsets were determined by fluorescence-activated cell sorting. a Graphs represent the percentage of CD45+ CD3+ and CD45+ CD19+ lymphocytes and the ratio CD45+ CD3+/CD45+ CD19 (sham, n = 3–6; saline, n = 3–10; AB, n = 3–6; MenSCs, n = 3–6; MenSCs + AB, n = 3–6). Histograms represent the mean ± standard error. b Representative dot plots of specific lymphocyte subsets described in (a) at 40 hours post-induction of sepsis and administration of different treatments. AB antibiotics, CLP cecal ligation and puncture, LB B lymphocytes, LT T lymphocytes, MenSCs menstrual derived mesenchymal stem cells, ns non-significant

Back to article page